Katherine A Vallis MBBS, PhD, MRCP, FRCR, FRCP(C)
Research Themes
Divisional Themes
- Cancer and Haematology
Group Members
- Bart Cornelissen, Laboratory Manager
- Sarah Able, Research Assistant
- Nadia Falzone, Oxford Nuffield Medical Fellow
- Mark Jackson, DPhil student
- Ketan Shah, CRF, DPhil student
- Philip Waghorn, PDF
- Neel Patel, CRF, DPhil student
- Hinlun Chu, DPhil student
- Georgina Royal, MS Student
- Cynthia Eccles, Research Radiographer, DPhil student
Selected Bibliography
- Vallis KA and Terry SYA (In Press) Relationship between chromatin structure and sensitivity to molecularly-targeted Auger electron radiation therapy. Int J Radiat Oncol Biol Phys.
- Cornelissen Bart, Darbar Sonali, Hernandez Rebecca, Kersemans Veerle, Tullis Iain, Barber Paul R, Smart Sean, Vojnovic Borivoj, Reilly Raymond, and Vallis Katherine A (2011) ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy. J Nucl Med, 52(5):776-83.
- Cornelissen Bart, Kersemans Veerle, Darbar Sonali, Thompson James, Shah Ketan, Sleeth Kate, Hill Mark A, and Vallis Katherine A (2011) Imaging DNA damage in vivo using gammaH2AX-targeted immunoconjugates. Cancer Res, 71(13):4539-49.
- Falzone Nadia, Nathan Roger, Myhra Sverre, Chakalova Radka, Altebaeumer Thomas, and Vallis Katherine (2011) Chemically amplified photoresist for high resolution autoradiography in targeted radiotherapy. Biomaterials, 32(26):6138-44.
| katherine.vallis@rob.ox.ac.uk | |
| Tel | +44 (0) 1865 2 25850 |
| Fax | +44 (0) 1865 2 25850 |
| PA | Anne-Marie Honeyman-Tafa |
Professor Katherine A Vallis
The goal of the Experimental Radiation Therapeutics Group is the development of novel radiopharmaceuticals to image and/or treat cancer.
Our four main research activities are: (1) The pre-clinical development of molecularly-targeted peptide-, antibody- and DNA-based radiotherapeutic agents, (2) Early phase clinical trials of novel radiotherapeutic agents, (3) The development of molecular imaging techniques (SPECT and PET) to diagnose and monitor cancer and (4) the investigation of the radiobiological effects of anticancer radiopharmaceuticals.
Biography
2006 - Senior Group Leader
Radiation Oncology & Biology
University of Oxford
2005 - Associate Professor in Radiation Oncology and Medical Biophysics
University of Toronto
1995-2006 - Staff Radiation Oncologist
Princess Margaret Hospital
Toronto
Awards Training and Qualifications
- 1995 Ph.D., University of Edinburgh
- 1981 MBBS, The Medical College of St. Bartholomew's Hospital, University of London
